In this episode, the faculty will review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonialowering therapies. The debate will also extend to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.

Faculty: Debbie Shawcross (Moderator), Rajiv Jalan (Faculty), Sara Montagnese (Faculty), Elliot Tapper (Faculty)

This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).